BRAF and colorectal cancer: Colorectal cancers that harbour the same BRAF(V600E) mutation are intrinsically resistant to BRAF inhibitors, due to feedback activation of the epidermal growth factor receptor (EGFR), although double or triple combination trials gave some benefit in terms of response rate [56].